BioCentury
ARTICLE | Product Development

More is less in CNS

June 19, 2006 7:00 AM UTC

Running clinical trials can be complicated when some of the disease symptoms a compound is designed to treat are also side effects of the compound. MediciNova Inc. ran into just such a conundrum with its serotonin (5-HT1A) receptor agonist, which it is developing to treat generalized anxiety disorder.

Last week, the company reported that MN-305 missed the primary endpoint in a Phase II/III trial. The company plans to try again later this year with another Phase II/III study using a lower dose it hopes will still alleviate symptoms with fewer side effects...